US
International

Preventing Acute Kidney Injury During Cardiac Surgery

Acute kidney injury (AKI) is reported in up to 30% of patients undergoing cardiac surgery and is a recognized independent predictor of both morbidity and mortality. RenalGuard Therapy may reduce this incidence.

Learn More

Reducing Incidence of Contrast-Induced Nephropathy

Contrast-Associated AKI (CA-AKI) is a form of Acute Renal Failure associated with exposure from image guided cardiology and radiology procedures of which 25% of these patients are at risk of AKI. RenalGuard has shown an average decrease of 62% in CA-AKI during clinical trials over 1400 patients.

Learn More

RenalGuard

Acute Kidney Injury (AKI) can occur during common hospital procedures including open heart surgery, minimally invasive heart cath procedures, and with ICU patients. RenalGuard is the only system offering a complete solution to patients at risk of AKI. The device is CE-marked for sale in Europe and a variety of countries throughout the world, and is under investigation in the U.S.

Click here to watch video.

RenalGuard is CE-marked for the intended use of temporary (up to 14 days) replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient’s intravascular fluid volume. The RenalGuard System is not intended for infusion of blood, blood components, medications, or nutritional fluids. All treatments administered via The RenalGuard System must be prescribed by a physician. RenalGuard Solutions, Inc. reserves the right to modify the specifications and features described herein, or discontinue manufacture of the product described at any time without prior notice or obligation. Caution - Investigational Device, Limited By United States Law to Investigational Use. This site contains medical information that is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns.